Allergen immunotherapy for allergic respiratory diseases

Area of Science:

• Immunology and Allergy
• Pharmacology and Therapeutics

Background:

• Allergen immunotherapy aims to induce tolerance to allergens through repeated administration.
• It is the only treatment with potential for disease modification, long-term remission, and prevention of new allergic sensitizations.
• Subcutaneous immunotherapy (SCIT) is effective for allergic rhinitis and asthma but carries risks like anaphylaxis.

Purpose of the Study:

• To review the efficacy, safety, and long-term benefits of SCIT and sublingual immunotherapy (SLIT).
• To highlight new findings on mechanisms, biomarkers, and novel approaches in allergen immunotherapy.
• To assess the current evidence for SLIT in seasonal and perennial allergies, and asthma, particularly in children.

Main Methods:

• Systematic review of existing literature on SCIT and SLIT.
• Evaluation of clinical trial data and observational studies.
• Analysis of research on immunological mechanisms and biomarkers.

Main Results:

• SLIT is an effective and safer alternative to SCIT, especially for seasonal allergies in adults and children.
• Evidence for SLIT in perennial allergies and asthma is less robust, particularly in pediatric populations.
• SCIT remains a proven treatment for allergic rhinitis and asthma, despite potential side effects.

Conclusions:

• Allergen immunotherapy, particularly SLIT, shows significant promise for managing allergic diseases.
• Further research is needed to establish the efficacy and safety of SLIT for perennial allergies and pediatric asthma.
• Advances in understanding mechanisms and biomarkers may lead to improved and novel immunotherapy strategies.